R2810-ONC-1901

Neoadjuvant cemiplimab: single-arm phase II, resectable II-IV (M0) cSCC → surgery.

pCR 51%; 54-mo EFS 76.2%, OS 79.4%.

Postop RT, cemiplimab or observation: investigator choice. This can't establish safe RT omission.

#ESMO26 #OncTwitter

https://doi.org/10.1200/JCO-26-02166